Centenial Surgical Suture Ltd has filed a formal complaint with BSE Limited alleging unusual trading activities and price manipulation in its scrip 531308. The company has requested urgent investigation into what it describes as manipulative and unethical trading practices that have artificially influenced its share price.

Complaint Details and Timeline

The complaint, dated February 16, 2026, was signed by Company Secretary Mahima Bathwal and addressed to BSE's Investigation and Surveillance Department. The company identified suspicious trading activities during the period from February 06, 2026 to February 13, 2026, involving multiple individuals engaging in small-volume transactions.

Alleged Trading Irregularities

The company reported that several individuals were trading in unusually small quantities of 1, 2, 3, 4, and 5 equity shares during the specified period. According to the complaint, these trading patterns appeared coordinated and designed to manipulate the last traded price (LTP) of the scrip.

Key concerns raised by the company include:

• Transactions executed at prices higher than the LTP
• Circular trading patterns with no real change in beneficial ownership
• Family members trading shares between each other in small quantities
• Artificial price increases not supported by corporate announcements or business developments

Detailed Trading Data Provided

The complaint includes Annexure A, which contains comprehensive trading data for the investigation period. The data shows both selling and buying activities across multiple demat accounts, with detailed information including:

Notable sellers included individuals who disposed of 50, 49, 36, 35, and 34 shares respectively, while buyers acquired shares in quantities ranging from 1 to 75 shares. The company emphasized that these sellers had sufficient quantities in their demat accounts but chose to sell in minuscule amounts.

Regulatory Violations Alleged

Centenial Surgical Suture has alleged violations of multiple SEBI regulations, specifically citing contraventions of:

• Regulations 3(a), (b), (c), and (d) of SEBI (Prohibition of Fraudulent and Unfair Trade Practices) Regulations, 2003
• Regulation 4(1), (2), (a), and (e) of PFUTP Regulations

The company characterized these activities as "serious misconduct and manipulation to increase the price of equity shares" and requested the issuance of Show Cause Notices (SCN) against the alleged manipulators.

Company's Position and Requests

The company has categorically denied any involvement by its promoters, directors, key managerial personnel, or their immediate relatives in the alleged manipulative trading. Management stated that no corporate announcements or material business changes justified the observed price movements.

The complaint emphasizes the company's commitment to protecting shareholder interests and maintaining market integrity. Management has offered full cooperation for any detailed investigation and requested that the matter be treated as an emergency requiring priority attention from regulatory authorities.

Centenial surgical suture Ltd. has announced the approval of its quarterly financial results through a regulatory filing with BSE Limited. The company's Board of Directors convened on February 12, 2026, to review and approve key financial disclosures for the reporting period.

Board Meeting Details

The board meeting was conducted on Thursday, February 12, 2026, with specific timing and procedural compliance maintained throughout the session.

Financial Results Approval

The primary agenda item addressed during the board meeting was the approval of standalone unaudited financial results. The results cover comprehensive financial performance for both quarterly and nine-month periods.

Regulatory Compliance

The announcement was made in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure follows Regulation 30 read with Schedule III(A)(IV) of the SEBI LODR framework, ensuring transparency and timely communication to stakeholders.

Corporate Governance

The filing was signed by Mahima Bathwal, Company Secretary & Compliance Officer, who holds membership number ACS A35069. The digital signature was applied on February 12, 2026, at 19:09:53 +05'30', confirming the authenticity and timing of the regulatory submission to BSE Limited.